Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. (Record no. 22657717)

MARC details
000 -LEADER
fixed length control field 02336 a2200613 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250516143904.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201408s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1029-2403
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3109/10428194.2013.790544
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Provencio, Mariano
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20140813
245 00 - TITLE STATEMENT
Title Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Leukemia & lymphoma
Date of publication, distribution, etc. Jan 2014
300 ## - PHYSICAL DESCRIPTION
Extent 51-5 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal, Murine-Derived
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Agents
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Combined Chemotherapy Protocols
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Consolidation Chemotherapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cyclophosphamide
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Doxorubicin
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Induction Chemotherapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Lymphoma, Follicular
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medication Adherence
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Neoplasm Grading
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Neoplasm Staging
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prednisone
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prognosis
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Risk Factors
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Rituximab
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Treatment Outcome
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Vincristine
General subdivision adverse effects
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Cruz Mora, Miguel Á
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Gómez-Codina, José
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Quero Blanco, Cristina
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Llanos, Marta
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name García-Arroyo, Francisco R
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name de la Cruz, Luis
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Gumá Padró, Josep
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Delgado Pérez, Juan R
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sánchez, Antonio
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Alvarez Cabellos, Ruth
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Rueda, Antonio
773 0# - HOST ITEM ENTRY
Title Leukemia & lymphoma
Related parts vol. 55
-- no. 1
-- p. 51-5
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.3109/10428194.2013.790544">https://doi.org/10.3109/10428194.2013.790544</a>
Public note Available from publisher's website

No items available.